Navigation Links
Fuisz Pharma Announces Intent to Divest Strategic Patent for Detection of Opioid Abuse; Seeks Offers for Patent through May 2013
Date:4/22/2013

MIAMI, April 22, 2013 /PRNewswire-USNewswire/ -- Fuisz Pharma today announced its intent to divest its strategic issued patent for the detection of opioid abuse (US 7,214,385 "Pharmaceutical Formulation Containing Dye").  This patent covers the use of dyes and staining agents in pharmaceutical dosage forms as a method to prevent the improper use of opioid drugs by visually demonstrating their misuse and abuse.  For example, where a patient abuses a drug like oxycodone through nasal snorting, this patented system leaves a stain in the nasal cavity that can be used by care givers, law enforcement, and family to determine that abuse is occurring. It does not leave a stain if taken properly by mouth.

Fuisz Pharma's Managing Member, Joseph Fuisz commented: "In the FDA's decision this month approving the withdrawal of the old Oxycontin® formulation for safety reasons thereby stopping generic companies from using that product as a reference drug, the FDA has given a strong economic incentive to innovators to deploy deterrent features to prevent abuse.  In reaching this conclusion, the FDA specifically cited intranasal abuse as well as evidence that the new Oxycontin® formulation reduced intranasal abuse."

Richard Fuisz , M.D., Founding Member, commented, "It is but a matter of time before there is an increasing recognition that abuse detection is an essential component of abuse deterrence. This is the bedrock patent of abuse recognition by the care giver, the emergency room personnel and law enforcement resulting in a powerful deterrent to abuse."

Mr. Joseph Fuisz continued: "The patented dye-stain system described in the '385 can be used independently as a feature, or stacked together with other deterrent features like crush resistance.  This ability to stack multiple features is particularly advantageous insofar is more deterrence is better.  Moreover, many formulation techniques for crush resistance do not enjoy patent protection.

"Divesting this asset will allow us to better focus on our other drug delivery assets, including the Saturn™ tablet designed for improved esophageal transit and increasingly a focal point of therapeutic and potential product liability concern with regard to unnecessary esophageal excoriation by a whole group of drugs that can cause damage when esophageal transit fails.

"We will accept offers for the '385 through the end of May 2013, but reserve the right to enter into a transaction earlier or otherwise refuse offers.  Interested parties should contact Fuisz Pharma."

Fuisz Pharma is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, diagnostics and having extensive experience working with big and specialty pharma. Fuisz Pharma has its headquarters in Miami.  www.fuisz.com.


'/>"/>
SOURCE Fuisz Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuisz llc Announces Induction of Richard C. Fuisz, M.D., into Georgetown Universitys 1789 Society.
2. Fuisz Pharma Announces Patent Allowance For New Tablet And Caplet Shapes That Promote Rapid, Reliable Esophageal Transit
3. Pharmagen to Present Strategic Vision for Solving Nations Parenteral Drug Shortage Crisis at 2013 BIO International Convention
4. New PAREXEL Report Defines The Next Generation Of Strategic Partnerships Between CROs And Biopharmaceutical Industry
5. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
6. Statement from the Cystic Fibrosis Foundation on Promising Phase 2 Clinical Trial Results of Kalydeco and VX-661 (Vertex Pharmaceuticals Inc.)
7. The Politics of Pharma: Washington, States, and the Courts Impact on the Industry
8. Biopharmaceutical Managed Care Strength Closely Intertwined with Marketplace Success
9. ADial Pharmaceuticals Announces Agreement With FDA For Phase III Trial Of AD04 For Alcohol Use Disorder In Patients Of Targeted Genotypes
10. Comparison of Biopharmaceutical Industry Between China and India 2013
11. Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE ... team that developed an innovative way to use nonlinear ... the delivery of new drugs. ... Clinical Dermatology Conference will show how researchers from BioPharmX ... Harvard Medical School used a suite of imaging techniques ...
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... wound care advancements to physician colleagues, skilled nursing facility medical directors and other ... Treacherous Waters of Wound Care." , "At many of these conferences we get ...
Breaking Medicine News(10 mins):